Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4357 vs novel androgen receptor pathway inhibitors in PSMA-positive progressive mCRPC
CTR20255041Phase 3Active
- Sponsor
- Hengrui Pharma
- Start
- Feb 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-4357 in prostate cancer (PCa), sponsored by Hengrui Pharma. Started Feb 2026; status: active.
02
Drugs
HRS-4357
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20255041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255041.